Compare MCFT & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCFT | BBOT |
|---|---|---|
| Founded | 1968 | 2016 |
| Country | United States | United States |
| Employees | N/A | 106 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 604.0M | 605.6M |
| IPO Year | 2015 | N/A |
| Metric | MCFT | BBOT |
|---|---|---|
| Price | $23.10 | $8.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $24.25 | $24.00 |
| AVG Volume (30 Days) | 154.5K | ★ 482.4K |
| Earning Date | 05-07-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $284,203,000.00 | N/A |
| Revenue This Year | $9.18 | N/A |
| Revenue Next Year | $8.23 | N/A |
| P/E Ratio | $72.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.19 | $7.00 |
| 52 Week High | $28.44 | $14.87 |
| Indicator | MCFT | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 60.58 |
| Support Level | $21.90 | $8.02 |
| Resistance Level | $23.58 | $9.50 |
| Average True Range (ATR) | 1.11 | 0.53 |
| MACD | -0.09 | 0.14 |
| Stochastic Oscillator | 22.84 | 59.91 |
MasterCraft Boat Holdings Inc designs, manufactures, and markets performance sport boats and outboard boats. The company is based in the United States and operates in three brand-specific segments. The MasterCraft segment generates the majority of the company's revenue and includes inboard boats for water skiing, wakeboarding, and wake surfing. The Pontoon segment produces pontoon boats at its Owosso, Michigan facility. Pontoon boats are used for general recreational boating. The Aviara segment produces luxury day boats at its Merritt Island, Florida facility. Aviara boats are used for general recreational boating.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.